RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Cortex Pharmaceuticals — Biotechnology Showcase 2015

33 slides from RespireRx Pharmaceuticals's conference presentation, Jan 13, 2015

  1. Slide 1: Cortex Pharmaceuticals, Inc. Biotechnology Showcase

    E)CuEX PHARMACEUTICALS, INC. Cortex Pharmaceuticals, Inc. Biotechnology Showcase January 13, 2015

  2. Slide 2: Forward Looking Statements

    PHARMACEUTICALS, INC. iz (OXTEX Forward Looking Statements The matters discussed in this presentation that are not historical facts are "forward-looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," "anticipates," “intends,” "exp

  3. Slide 3: Background

    Background 2013 * Insolvent & near bankruptcy No ongoing operations Lost dronabinol license Deficient in SEC reporting Approx. $5M market cap Today + Non-bankruptcy reorganization + New capital raised + Re-gained dronabinol license * Will be current in SEC reporting by 2/15/2015 * Approx. $25M marke

  4. Slide 4: Management and Directors

    Management and Directors Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell John Greer Katie MacFarland James Sapirstein Chairman, CEO VP, Sec/Treas, Director CFO, Director Senior VP R& D Chairman, Scientific Advisory Board Prof & Dir. Neuroscience Ctr., U. Alberta Director, CCO Agile Ther

  5. Slide 5: Cortex Drug Platforms

    Cortex Drug Platforms Ampakines * Positive allosteric modulators of AMPA glutamate receptors * Positive effects for treatment of drug-induced respiratory depression in Phase 2A studies * Positive effects for treatment of central sleep apnea in Phase 2A study * Positive effects for treatment of ADHD

  6. Slide 6: Cortex Drug Platforms

    Cortex Drug Platforms Ampakines * Positive allosteric modulators of AMPA glutamate receptors + Positive effects for treatment of drug-induced respiratory depression in Phase 2A studies + Positive effects for treatment of central sleep apnea in Phase 2A study * Positive effects for treatment of ADHD

  7. Slide 7: Key Company Highlights

    Cortex is a leader in the discovery and development of innovative pharmaceuticals for the treatment of breathing disorders Key Company Highlights Drug-induced respiratory depression (RD) - ampakines ° Acute use - surgical anesthesia with propofol e Semi-acute use — post-surgical pain management with

  8. Slide 8: Large Market with Unmet Need

    Cortex is a leader e discovery and development of innovative pharmaceuticals for the treatment of breathing disorders Large Market with Unmet Need + Drug-induced Respiratory Depression (RD) - Patients treated with anesthetic, analgesic and/or sedatives in association with surgery (12 million/yr) or

  9. Slide 9: Ampakines - Positive Allosteric Modulators at AMPA Glutamate Receptors

    AMPAKINES - Positive Allosteric Modulators at AMPA Glutamate Receptors AMPA Receptors Mediate Synaptic Transmission in the Brain » Glutamate is the major excitatory neurotransmitter in the CNS » Fast excitatory transmission is mediated by AMPA-type glutamate receptors » Ampakines are positive, allos

  10. Slide 10: Ampakines — Novel Treatment for Respiratory Depression

    PAKINES — Novel Treatment for Respiratory Depressio: Pa PreBotzinger © PreBétzinger Complex ce Complex + Neurons in this brainstem region control inspiratory breathing rhythm + PreBotC neurons use AMPA receptors for signaling + Opiates and other depressants mediate their inhibitory effects on breath

  11. Slide 11: Acute Drug-induced Respiratory Depression

    Acute Drug-induced Respiratory Depression + Most frequent lethal side effect of opiate use is respiratory depression (RD) + In-patient, post surgical opiate use (~12M patients/year) increases risk for R * RD also occurs during anesthetic procedures (e.g. colonoscopy) with propofol (20 MM procedures/

  12. Slide 12: CX1739: An Oral Phase 2 Ampakine

    CX1739: An Oral Phase 2 Ampakine » Stage of Development ° Completed Phase 1 in healthy volunteers and Phase 2a in central sleep apnea ° Ready for Phase 2A studies in opiate- and propofol-induced respiratory depression and central sleep apnea » Targeted Indication ° Prevention of propofol-induced res

  13. Slide 13: Reversal of Opioid-induced Respiratory Depression with an Ampakine in Rats

    Reversal of Opioid-induced Respiratory Depression with an Ampakine in Rats CX1739 injection Fentanyl Fentanyl AMIN ni 4 Prolonged opiate-induced CX1739 reverses opiate-induced respiratory depression leads to respiratory depression and lethality prevents lethality 10s 13

  14. Slide 14: Reversal of Propofol-induced RD With an Ampakine in the Rat

    Reversal of Propofol-induced RD With an Ampakine in the Rat Experimental Design: - Administer a lethal dose of propofol to rats - Inject CX1739 within 1 minute Propofol a Propofol + CX1739 TT Onn 14

  15. Slide 15: Clinical studies in healthy volunteers with CX717

    » Two clinical studies were run in normal, healthy volunteers with CX717, an earlier Ampakine » Moderate respiratory depression was induced experimentally by infusion of the opioid, Alfentanil » Respiratory and analgesia end-points were measured Oral CX71 vented the c ‘ to depression without impacti

  16. Slide 16: Respiratory rate in the presence of Alfentanil

    C—Placebo eg cx717 *P<0.01 NS - Not Significant Baseline +Alfentanil +Naloxone tory rate in the presence of Alfentanil Data are expressed as the basal respiratory rate. N= 15 and 16 per group. CX717 dose is 1 500mg. 16

  17. Slide 17: Analgesia was unaffected by CX717

    (Placebo @CX717 a NS Delivery of a electrical stimulation to finger Pain Sensitivity 5 S a 0.0: Baseline _+Alfentanil__ +Naloxone Analgesia was unaffected by CX717 Data are expressed as the pain sensitivity, normalized to the Baseline measurement. N= 15 and 16 per group. CX717 dose is 1500mg. ¥

  18. Slide 18: Pompe Disease

    POMPE DISEASE * Autosomal recessive metabolic disorder caused by an accumulation of lysosomal glycogen due to a deficiency of alpha glucosidase * Damages muscle and nerve cells throughout the body + Respiratory failure is the most common cause of death * Replacement enzyme therapy a :

  19. Slide 19: Mouse Model of Pompe Disease

    MOUSE MODEL OF POMPE DISEASE Effects of Ampakine on Minute Volume 20 . . mmm =Vehicle t = _ 15 mg/kg [=a 30mg/kg Elmallah et al, in press 19

  20. Slide 20: Infant Apnea - Animal Model in Premature Rats

    INFANT APNEA - ANIMAL MODEL IN PREMATURE RATS Breaths/min Apnea/min 150) LS = mw Postnatal 100 | alia mi Prenatal1 (n=30) apt mi Postnatal 2 (n=16) o 1 y Ren, Ding and Greer, in press 20

  21. Slide 21: Effects of CX1739 on Breathing in Premature Rat Pups

    EFFECTS OF CX1739 ON BREATHING IN PREMATURE RAT PUPS © HPCD © CX1739 (10 mg/kg) fr* Vr Ve* — Apnea* 160 e S 140 7 i i a £3 A 2 12040 8 = oe e & P s 10+ # ¢ 2 = = z e 2 8 g ‘3 E 80 Oo e ~ 60 : 40 Ren, Ding and Greer, in press a

  22. Slide 22: CX1942: A Soluble AMPA-PAM

    CX1942: A Soluble AMPA-PAM » Mechanism of Action ° A Positive Allosteric Modulator of AMPA receptors (AMPA-PAM) ° Water-soluble for injectable dosage forms » Stage of Development ° Injectable routes being studied in animal models of respiratory depression e Supported by SBIR contract » Targeted Indi

  23. Slide 23: Sleep Apnea

    Sleep Apnea ° Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10s during sleep ° Three types: Obstructive, Central & Mixed The Sleep Apnea Market is Large ° 18 million U.S. adults with moderate or severe sleep apnea ° Market potential for sleep apnea is $3 - 9

  24. Slide 24: Obstructive Sleep Apnea (OSA)

    Obstructive Sleep Apnea (OSA) » Obstructive sleep apnea (OSA) involves a decrease or complete halt in airflow despite an ongoing effort to breathe during sleep ° Occurs when the muscles relax during sleep ° Soft tissue in back of throat collapses and obstructs upper airway » Affects 18 MM adults in

  25. Slide 25: Obstructive Sleep Apnea: Scope of the Problem in the US

    Obstructive Sleep Apnea Scope of the Problem in the US Estimated Annual Annual Indicated Disease State US Estimated Drug Therapy Prevalence | Cost to Society| Expenditures OsAts 18.0MM | $75.0 Billion $o Asthma®7 16.4MM | $18.3 Billion $13.5 Billion Hypertension®°} 43.2MM | $73.4 Billion $48.5 Billi

  26. Slide 26: CPAP Efficacy is Greatly Limited by Patient Compliance

    CPAP Efficacy is Greatly Limited by Patient Compliance Works as an air splint to keep upper airway open during sleep 30% of patients prescribed CPAP never initiate treatment when prescribed a machine Over 50% of patients stop using CPAP in the first year of use ; may only wear 3- \ ~ 4h/night Nj NY

  27. Slide 27: Dronabinol for Treatment of OSA: A Phase 2 Compound

    Dronabinol for Treatment of OSA: A Phase 2 Compound v Mechanism of Action ° Dronabinol is (A-9)THC, a cannabinoid agonist Commercial Status ° FDA approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy ° Schedule III drug available b

  28. Slide 28: Dronabinol Phase 2A Clinical Study in OSA

    Dronabinol Phase 2A Clinical Study in OSA | » Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA » Randomized to Placebo (N=5) or Dronabinol (N=17) for 21 days © 2.5, 5 and 10 mg/night studied with weekly dose escalation » Overnight polysomnogram (PSG) at base

  29. Slide 29: Reduction in Sleep Apnea

    Reduction in Sleep Apnea Dronabinol Reduced the AHI in OSA Subjects AHI Mean % Change from Baseline to End of Treatment 40% 30% 20% 10% Dronabinol 0% Placebo 10% -20% -30% 40%

  30. Slide 30: Apnea Suppression as a Function of Dose

    AAHI versus Baseline Apnea Suppression as a Functi of Dose NN i \| n=17 n= 13 n=8 The plasma half-life of dronabinol is 2 — 4 hours. w Ist Half m 2nd Half 30

  31. Slide 31: Dronabinol Phase 2B Trial in Chronic, Obstructive Sleep Apnea

    Dronabinol Phase 2B Trial in Chronic, Obstructive Sleep Apnea o Phase 2B study in progress at University of Illinois ° 120 subjects (40/group, 6 wks dosing) ° Doses: Placebo, 2.5 mg, 10 mg qd ° Study costs funded by NIH Grant for $5 MM ° Top line data by 3Q2015 a

  32. Slide 32: Protecting Dronabinol in the Marketplace

    Protecting Dronabinol in the Marketplace » Issued Method-of-Use patent for dronabinol and OSA e Expires in 2025 » Proprietary dosage and pulse-dose formulation to provide efficacy over entire night e Pending patent applications » Generics and medical marijuana are not covered for this use by third p

  33. Slide 33: Key Objectives for the Next 12 Months

    Key O Compound Dronabinol CX1739 CX1739/C X717 CXx1942 ctives for Indication Obstructive Sleep Apnea Opiate-induced RD Propofol-induced RD Pompe Disease Injectable for RD Status Estimated Start Date Phase IIB started Phase IIA 1Q2015 Phase IIA 3Q2015 Phase IIA mid-2015 Pre-clinical 3Q2014 studies Es

Cortex Pharmaceuticals — Biotechnology Showcase 2015 on 6ix